436.00
price up icon0.45%   1.97
after-market After Hours: 435.00 -1.00 -0.23%
loading
Vertex Pharmaceuticals Inc stock is traded at $436.00, with a volume of 1.43M. It is up +0.45% in the last 24 hours and down -11.46% over the past month. Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$434.03
Open:
$428.68
24h Volume:
1.43M
Relative Volume:
0.86
Market Cap:
$111.96B
Revenue:
$11.10B
Net Income/Loss:
$-988.90M
P/E Ratio:
-111.22
EPS:
-3.92
Net Cash Flow:
$-1.26B
1W Performance:
-0.60%
1M Performance:
-11.46%
6M Performance:
-3.32%
1Y Performance:
-3.28%
1-Day Range:
Value
$427.43
$436.59
1-Week Range:
Value
$427.43
$448.00
52-Week Range:
Value
$377.85
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
Name
Vertex Pharmaceuticals Inc
Name
Phone
(617) 341-6393
Name
Address
50 NORTHERN AVENUE, BOSTON, MA
Name
Employee
6,100
Name
Twitter
@VertexPharma
Name
Next Earnings Date
2025-02-10
Name
Latest SEC Filings
Name
VRTX's Discussions on Twitter

Compare VRTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.00 112.64B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
ONC
Beigene Ltd Adr
241.43 27.03B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 40.86M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.34 64.17B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.06 6.07B 0 -153.72M -103.81M -2.00

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-07-25 Downgrade Wolfe Research Outperform → Peer Perform
May-06-25 Downgrade Leerink Partners Outperform → Market Perform
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Feb-12-25 Upgrade Canaccord Genuity Sell → Hold
Feb-11-25 Upgrade Canaccord Genuity Sell → Hold
Jan-30-25 Downgrade Wells Fargo Overweight → Equal Weight
Dec-20-24 Reiterated H.C. Wainwright Buy
Dec-19-24 Downgrade Oppenheimer Outperform → Perform
Dec-09-24 Upgrade Jefferies Hold → Buy
Nov-14-24 Initiated Citigroup Buy
Oct-16-24 Initiated Scotiabank Sector Perform
Oct-10-24 Resumed Raymond James Mkt Perform
Aug-05-24 Downgrade Barclays Overweight → Equal Weight
Jun-27-24 Initiated Redburn Atlantic Buy
Apr-11-24 Upgrade Evercore ISI In-line → Outperform
Feb-15-24 Initiated Wolfe Research Outperform
Feb-06-24 Downgrade Evercore ISI Outperform → In-line
Feb-02-24 Downgrade Bernstein Outperform → Mkt Perform
Jan-31-24 Downgrade Maxim Group Buy → Hold
Jan-31-24 Downgrade Robert W. Baird Neutral → Underperform
Jan-24-24 Downgrade Canaccord Genuity Hold → Sell
Dec-14-23 Reiterated RBC Capital Mkts Sector Perform
May-30-23 Initiated William Blair Outperform
May-04-23 Resumed Piper Sandler Overweight
Mar-21-23 Initiated Bernstein Outperform
Jan-18-23 Initiated Canaccord Genuity Hold
Jan-17-23 Upgrade SVB Leerink Mkt Perform → Outperform
Dec-19-22 Downgrade Jefferies Buy → Hold
Jul-13-22 Initiated Cantor Fitzgerald Overweight
Jun-01-22 Upgrade Maxim Group Hold → Buy
May-23-22 Initiated SVB Leerink Mkt Perform
May-06-22 Downgrade Robert W. Baird Outperform → Neutral
May-03-22 Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-03-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-27-22 Reiterated JP Morgan Overweight
Jan-27-22 Reiterated Morgan Stanley Underweight
Jan-27-22 Reiterated RBC Capital Mkts Outperform
Jan-27-22 Reiterated Stifel Hold
Jan-27-22 Reiterated Wolfe Research Outperform
Jan-20-22 Upgrade BMO Capital Markets Market Perform → Outperform
Dec-09-21 Initiated Wells Fargo Overweight
Nov-19-21 Initiated BMO Capital Markets Market Perform
Nov-19-21 Downgrade Piper Sandler Overweight → Neutral
Sep-09-21 Downgrade Stifel Buy → Hold
Sep-07-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-20-21 Downgrade SVB Leerink Mkt Perform → Underperform
Jul-19-21 Resumed Wolfe Research Outperform
Jul-01-21 Initiated Raymond James Mkt Perform
Jun-11-21 Downgrade Daiwa Securities Outperform → Neutral
Feb-23-21 Upgrade Robert W. Baird Neutral → Outperform
Feb-02-21 Reiterated H.C. Wainwright Buy
Dec-30-20 Initiated Daiwa Securities Outperform
Nov-30-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-20-20 Initiated Bernstein Outperform
Oct-28-20 Initiated UBS Buy
Jul-31-20 Reiterated H.C. Wainwright Buy
Jul-08-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-30-20 Reiterated H.C. Wainwright Buy
Apr-28-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-04-20 Initiated Barclays Overweight
Jan-31-20 Downgrade Robert W. Baird Outperform → Neutral
Nov-19-19 Upgrade Guggenheim Neutral → Buy
Nov-12-19 Initiated SunTrust Buy
Oct-17-19 Resumed BofA/Merrill Buy
Sep-03-19 Upgrade Goldman Neutral → Buy
Aug-01-19 Downgrade Needham Buy → Hold
May-23-19 Resumed Citigroup Buy
May-21-19 Initiated Credit Suisse Outperform
Apr-12-19 Initiated Evercore ISI In-line
Mar-26-19 Upgrade William Blair Mkt Perform → Outperform
Mar-19-19 Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19 Downgrade Maxim Group Buy → Hold
View All

Vertex Pharmaceuticals Inc Stock (VRTX) Latest News

pulisher
May 24, 2025

2 Monster Growth Stocks to Buy and Hold for 10 Years - The Motley Fool

May 24, 2025
pulisher
May 23, 2025

Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline? (NASDAQ:VRTX) - Seeking Alpha

May 23, 2025
pulisher
May 23, 2025

Argus Adjusts Price Target on Vertex Pharmaceuticals to $525 From $550 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Vertex Pharmaceuticals (VRTX) Downgraded Due to High Inventory Levels | VRTX Stock News - GuruFocus

May 23, 2025
pulisher
May 22, 2025

Vertex Pharmaceuticals (VRTX) Announces $4 Billion Share Buyback Program - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN

May 22, 2025
pulisher
May 21, 2025

Vertex Pharma announces new share buybacks worth up to $4B - MSN

May 21, 2025
pulisher
May 21, 2025

Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish? - MSN

May 21, 2025
pulisher
May 21, 2025

Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com

May 21, 2025
pulisher
May 21, 2025

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - Yahoo Finance

May 21, 2025
pulisher
May 20, 2025

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Benzinga

May 20, 2025
pulisher
May 20, 2025

Vertex Pharma stock gains on share buybacks (VRTX:NASDAQ) - Seeking Alpha

May 20, 2025
pulisher
May 19, 2025

Vertex Pharmaceuticals (VRTX) Announces New $4 Billion Stock Rep - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Vertex Pharmaceuticals Authorizes $4 Billion In Additional Share Repurchases - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

August 15th Options Now Available For Vertex Pharmaceuticals (VRTX) - Nasdaq

May 19, 2025
pulisher
May 19, 2025

VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss - Yahoo Finance

May 19, 2025
pulisher
May 15, 2025

Vertex to Participate in Upcoming Investor Conferences | VRTX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Vertex to Participate in Upcoming Investor Conferences - Business Wire

May 15, 2025
pulisher
May 14, 2025

Vertex Pharmaceuticals Holds Annual Shareholder Meeting - TipRanks

May 14, 2025
pulisher
May 14, 2025

Stifel maintains hold on Vertex stock with $494 target - Investing.com

May 14, 2025
pulisher
May 13, 2025

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga

May 13, 2025
pulisher
May 13, 2025

Best Biotech Stocks to Buy in 2025 - MarketBeat

May 13, 2025
pulisher
May 13, 2025

Fund Update: TRILLIUM ASSET MANAGEMENT, LLC added 38,854 shares of VERTEX PHARMACEUTICALS ($VRTX) to their portfolio - Nasdaq

May 13, 2025
pulisher
May 12, 2025

Our future journey in cystic fibrosis - Vertex Pharmaceuticals

May 12, 2025
pulisher
May 11, 2025

Vertex says late-stage studies of VX-659 triple combination therapy in CF hit main goals - FirstWord Pharma

May 11, 2025
pulisher
May 11, 2025

ViewPoints: Vertex settles on a dynastic successor - FirstWord Pharma

May 11, 2025
pulisher
May 11, 2025

Vertex's VX-445 triple combination regimen achieves main goals of two late-stage studies in CF - FirstWord Pharma

May 11, 2025
pulisher
May 11, 2025

Vertex moves forward with regulatory filings after selecting VX-445 for triple-combination regimen in CF - FirstWord Pharma

May 11, 2025
pulisher
May 11, 2025

Is Vertex Pharmaceuticals (VRTX) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey

May 11, 2025
pulisher
May 11, 2025

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? - Benzinga

May 11, 2025
pulisher
May 10, 2025

VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - MSN

May 10, 2025
pulisher
May 09, 2025

Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft - CNBC

May 09, 2025
pulisher
May 09, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Vertex Pharmaceuticals Incorporated Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks - MSN

May 09, 2025
pulisher
May 08, 2025

Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss - MSN

May 08, 2025
pulisher
May 08, 2025

Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025
pulisher
May 07, 2025

Vertex Says 20,000 Prescriptions Filled for Non-Opioid Pain Drug - MSN

May 07, 2025
pulisher
May 07, 2025

Leerink Partners Downgrades Vertex Pharmaceuticals (XTRA:VX1) - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Vertex Pharmaceuticals (VRTX) Faces Downgrade After Q1 Revenue Miss - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Vertex Pharma stock downgraded at Wolfe (VRTX:NASDAQ) - Seeking Alpha

May 07, 2025
pulisher
May 07, 2025

Cystic fibrosis Market: Epidemiology, Therapies, Companies, - openPR.com

May 07, 2025
pulisher
May 07, 2025

Leerink Partners Downgrades Vertex Pharmaceuticals (BIT:1VRTX) - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Vertex Pharmaceuticals (VRTX) Sees Target Price Increase to $499 by Barclays | VRTX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - AOL.com

May 07, 2025
pulisher
May 07, 2025

Leerink Partners Downgrades Vertex Pharmaceuticals (WBAG:VRTX) - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Wolfe Research Downgrades Vertex Pharmaceuticals to Peer Perform From Outperform - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Vertex Pharmaceuticals (VRTX) Downgraded Amid Revenue Concerns | VRTX Stock News - GuruFocus

May 07, 2025

Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.335
price up icon 6.39%
$588.34
price down icon 1.43%
$75.06
price up icon 3.26%
$4.25
price up icon 0.48%
$289.96
price up icon 0.33%
Cap:     |  Volume (24h):